Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

PD-1/PD-L1 checkpoint blockades have achieved significant progress in several kinds of tumours. Pembrolizumab, which targets PD-1, has been approved as a first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with positive PD-L1 expression. However, PD-1/PD-L1 checkpoint block...

Full description

Saved in:
Bibliographic Details
Published in:J Exp Clin Cancer Res
Main Authors: Wang, Xin, Guo, Gaochao, Guan, Hui, Yu, Yang, Lu, Jie, Yu, Jinming
Format: Artigo
Language:Inglês
Published: BioMed Central 2019
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6380009/
https://ncbi.nlm.nih.gov/pubmed/30777100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1085-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items